Evidence map›Paper›PMID 25691576›Full record

ArticleThe Journal of biological chemistry2015

5-Azacytidine-induced protein 2 (AZI2) regulates bone mass by fine-tuning osteoclast survival.

Kenta Maruyama, Masahiro Fukasaka, Satoshi Uematsu, Osamu Takeuchi, Takeshi Kondo, Tatsuya Saitoh, Mikaël M Martino, Shizuo Akira

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Kenta MaruyamaFrom the Laboratory of Host Defense, World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871, maruyama@biken.osaka-u.ac.jp.
Masahiro FukasakaFrom the Laboratory of Host Defense, World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871, the Life Science Research Center, Corporate R&D Development Division, Nitto Denko Corporation, 1-1-2 Shimohozumi, Ibaraki, Osaka 567-8680, and.
Satoshi Uematsuthe Division of Innate Immune Regulation, International Research and Development Center for Mucosal Vaccine, Institute for Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639.
Osamu Takeuchithe Laboratory of Infection and Prevention, Institute for Virus Research, Kyoto University, 53 Shogokuin Kawara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
Takeshi KondoFrom the Laboratory of Host Defense, World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871.
Tatsuya SaitohFrom the Laboratory of Host Defense, World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871, the Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871.
Mikaël M MartinoFrom the Laboratory of Host Defense, World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871.
Shizuo AkiraFrom the Laboratory of Host Defense, World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871, the Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, sakira@biken.osaka-u.ac.jp.
Osaka International University · JPOsaka University · JPImmune Regulation (United Kingdom) · GBKyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

5-Azacytidine-induced protein 2 (AZI2) is a TNF receptor (TNFR)-associated factor family member-associated NF-κB activator-binding kinase 1-binding protein that regulates the production of IFNs. A previous in vitro study showed that AZI2 is involved in dendritic cell differentiation. However, the roles of AZI2 in immunity and its pleiotropic functions are unknown in vivo. Here we report that AZI2 knock-out mice exhibit normal dendritic cell differentiation in vivo. However, we found that adult AZI2 knock-out mice have severe osteoporosis due to increased osteoclast longevity. We revealed that the higher longevity of AZI2-deficient osteoclasts is due to an augmented activation of proto-oncogene tyrosine-protein kinase Src (c-Src), which is a critical player in osteoclast survival. We found that AZI2 inhibits c-Src activity by regulating the activation of heat shock protein 90 (Hsp90), a chaperone involved in c-Src dephosphorylation. Furthermore, we demonstrated that AZI2 indirectly inhibits c-Src by interacting with the Hsp90 co-chaperone Cdc37. Strikingly, administration of a c-Src inhibitor markedly prevented bone loss in AZI2 knock-out mice. Together, these findings indicate that AZI2 regulates bone mass by fine-tuning osteoclast survival.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsBone DensityCell Cycle ProteinsCell DifferentiationCells, CulturedCell SurvivalCSK Tyrosine-Protein KinaseHSP90 Heat-Shock ProteinsImmunoblottingMice, KnockoutMolecular ChaperonesMyeloid CellsOsteoclastsOsteoporosissrc-Family KinasesAdaptor Proteins, Signal TransducingAZI2 protein, mouseCdc37 protein, mouseCell Cycle ProteinsCSK Tyrosine-Protein KinaseHSP90 Heat-Shock ProteinsMolecular Chaperonessrc-Family KinasesAZI2Cell DeathMacrophageOsteoblastOsteoclastOsteoporosis

Identifiers

PMID25691576
PMCPMC4392245
OpenAlexW2075810070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.